Alabama Patent of the Month – January 2024

CerFlux, Inc., innovators in cancer research, have been granted a patent for their proprietary biomimetic array device, poised to redefine the landscape of biological sample analysis. This groundbreaking invention presents a meticulously crafted cassette, featuring a microchamber array and microchannels that pave the way for innovative applications in fluid transport and equal exposure of biological samples.

At the heart of this device lies a series of microchambers in fluid communication with microchannels, forming a network primed for intricate biological sample interactions. The top interface of each microchamber, open to its external environment, serves as a receptacle for biological samples. This setup allows the sample to draw fluid from the microchambers, pulling the same volume from each chamber.

The biomimetic array device also introduces an inlet region, where wells and inlet channels synergistically contribute to the transport of approximately equal volumes of fluid from each well to every microchamber in communication with it. This design ensures a harmonized distribution of fluid, fostering consistency in exposure across the microchamber array.

Often biological samples are used to test the efficacy of a treatment option. For instance, a biological sample of a tumor tissue slice can be exposed to several treatment options and observed for cell viability and outcomes. With an effective biomimetic array device, this testing can be performed with greater precision and accuracy.

CerFlux’s biomimetic array device is not merely a technological marvel; it represents a paradigm shift in biological sample analysis. With its innovative design and meticulous attention to detail, this invention opens doors to a myriad of possibilities in therapeutic evaluation, disease modeling, and preclinical research. 

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts